Vor Biopharma VOR Insider Ownership

Updated Oct 16, 2026

Across the past 12 months, open-market trades by Vor Biopharma insiders were all sales, totaling $82.76 million (4.19Mn shares).

• Behind Vor Biopharma's open-market sales in the past 12 months were 2 insiders, and no insider bought.
• Ra Capital Management, L.P. (10% owner) led open-market sales of Vor Biopharma stock over the past 12 months with $81.57 million (4.15Mn shares), most recently on July 16, 2026.
• Beyond open-market trades, insiders at Vor Biopharma acquired 2.1Mn shares through option exercises and conversions in the last 12 months.
• Per Business Quant data, Vor Biopharma insiders hold 1.28Mn shares in total based on their latest Form 4 filings.
• Direct holdings account for 1.28Mn shares (99.96%) of VOR's insider total, and indirect holdings through trusts, partnerships and family members for 500 shares (0.04%).
• VOR's insider total is spread across 8 insiders who have filed a Form 4 in the past two years.
• Vor Biopharma's three largest insider shareholders, based on their latest Form 4 filings, are Reprogrammed Interchange LLC (10% owner, 1.17Mn shares), Qing Che Zuraw (Chief Development Officer, 46.85K shares) and Robert Ang (President and CEO, 45.57K shares).
• Reprogrammed Interchange LLC alone accounts for 91.01% of the shares held by Vor Biopharma insiders.
• Institutional holders reported 89.08% of Vor Biopharma's outstanding shares for Q2 2026; insiders' latest Form 4 filings put their stake at about 2.35%, and other investors, including the public, hold the remaining 8.57%.
• Over the past 12 months, 13 insiders reported transactions in Vor Biopharma stock in 29 Form 4 filings.
• This summary of Vor Biopharma insider activity covers Form 4 filings through October 5, 2026.